MX367034B - Formulacion para dominios de union biespecificos de celulas-t (bites). - Google Patents

Formulacion para dominios de union biespecificos de celulas-t (bites).

Info

Publication number
MX367034B
MX367034B MX2015005700A MX2015005700A MX367034B MX 367034 B MX367034 B MX 367034B MX 2015005700 A MX2015005700 A MX 2015005700A MX 2015005700 A MX2015005700 A MX 2015005700A MX 367034 B MX367034 B MX 367034B
Authority
MX
Mexico
Prior art keywords
bites
bispecific
formulation
cell engagers
antigen binding
Prior art date
Application number
MX2015005700A
Other languages
English (en)
Other versions
MX2015005700A (es
Inventor
Carsten Olbrich
Jörg Peters
Thomas Bunte
Jonas Winter
Thomas Trill
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MX2015005700A publication Critical patent/MX2015005700A/es
Publication of MX367034B publication Critical patent/MX367034B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas estables que contienen polipéptidos con por lo menos dos dominios de unión a antígeno y que son especialmente adecuadas para su administración subcutánea. La invención pone a disposición composiciones líquidas que minimizan la formación de agregados indeseados de polipéptidos (dímeros y/o multímeros). La presente invención pone además a disposición un método para minimizar la agregación de polipéptidos con dominios de unión a péptidos en composiciones líquidas.
MX2015005700A 2012-11-06 2013-11-05 Formulacion para dominios de union biespecificos de celulas-t (bites). MX367034B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12191493 2012-11-06
PCT/EP2013/073024 WO2014072277A1 (de) 2012-11-06 2013-11-05 Formulierung für bispecific t-cell-engangers (bites)

Publications (2)

Publication Number Publication Date
MX2015005700A MX2015005700A (es) 2015-08-20
MX367034B true MX367034B (es) 2019-08-02

Family

ID=47143702

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005700A MX367034B (es) 2012-11-06 2013-11-05 Formulacion para dominios de union biespecificos de celulas-t (bites).

Country Status (27)

Country Link
US (1) US11052128B2 (es)
EP (1) EP2916866B1 (es)
JP (1) JP6321667B2 (es)
KR (1) KR20150082328A (es)
CN (1) CN104780940B (es)
AR (1) AR093365A1 (es)
AU (2) AU2013343638B2 (es)
CA (1) CA2890166C (es)
CY (1) CY1120391T1 (es)
DK (1) DK2916866T3 (es)
ES (1) ES2676468T3 (es)
HK (1) HK1211215A1 (es)
HR (1) HRP20181021T1 (es)
HU (1) HUE038151T2 (es)
IL (1) IL238615A0 (es)
LT (1) LT2916866T (es)
MX (1) MX367034B (es)
NZ (1) NZ707895A (es)
PL (1) PL2916866T3 (es)
PT (1) PT2916866T (es)
RS (1) RS57394B1 (es)
RU (1) RU2679124C2 (es)
SG (1) SG11201502730SA (es)
SI (1) SI2916866T1 (es)
TR (1) TR201809507T4 (es)
TW (1) TWI615158B (es)
WO (1) WO2014072277A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016019969A1 (en) 2014-08-08 2016-02-11 Ludwig-Maximilians-Universität München Subcutaneously administered bispecific antibodies for use in the treatment of cancer
MX2021003628A (es) * 2018-10-01 2021-05-27 Amgen Inc Metodos para reducir la agregacion de anticuerpos biespecificos.
US20200199232A1 (en) * 2018-12-19 2020-06-25 City Of Hope Baff-r bispecific t-cell engager antibody
AU2020370372A1 (en) * 2019-10-25 2022-05-12 Amgen Inc. Compositions and methods for minimizing protein loss at low protein concentrations
CN115968867B (zh) * 2023-03-21 2023-07-14 天津外泌体科技有限公司 外泌体冻干保护剂和外泌体冻干制剂的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
EP1767225A1 (en) 2005-09-21 2007-03-28 Insense Limited Method for stabilisation of a protein solution by addition of hydroxyl radical quenchers and its sterilisation by ionising radiation
GB0626021D0 (en) 2006-12-29 2007-02-07 Insense Ltd The stabilisation of proteins
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
DK2520590T3 (en) 2007-04-03 2018-11-12 Amgen Res Munich Gmbh HERBIC SPECIFIC BINDING DOMAIN
CN101675077B (zh) 2007-04-03 2013-09-04 安进研发（慕尼黑）股份有限公司 跨种特异性的双特异性结合剂
WO2009070642A1 (en) * 2007-11-28 2009-06-04 Medimmune, Llc Protein formulation
AR070316A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
US7681537B2 (en) * 2008-08-17 2010-03-23 Cummins Intellectual Properties, Inc. Gas extractor for an engine coolant system
CN102171248B (zh) * 2008-10-01 2015-07-15 安进研发（慕尼黑）股份有限公司 种间特异性PSMAxCD3双特异性单链抗体
WO2010037837A2 (en) * 2008-10-01 2010-04-08 Micromet Ag Bispecific single chain antibodies with specificity for high molecular weight target antigens
KR20120027031A (ko) 2009-06-18 2012-03-20 와이어쓰 엘엘씨 소형 모듈 면역제약용 동결건조 제제
RU2548772C2 (ru) 2009-11-20 2015-04-20 Биокон Лимитед Составы антитела
CN102946858B (zh) * 2010-05-10 2015-09-30 英塔斯制药有限公司 含有免疫球蛋白Fc的多肽的液体制剂
JP2014510730A (ja) * 2011-03-16 2014-05-01 サノフイ デュアルｖ領域抗体様タンパク質の使用
WO2012143902A1 (en) * 2011-04-22 2012-10-26 Wyeth Llc Compositions relating to a mutant clostridium difficile toxin and methods thereof

Also Published As

Publication number Publication date
HUE038151T2 (hu) 2018-10-29
CN104780940B (zh) 2017-11-07
AU2013343638A1 (en) 2015-05-28
SI2916866T1 (en) 2018-08-31
TW201438764A (zh) 2014-10-16
PT2916866T (pt) 2018-07-10
AU2018214096A1 (en) 2018-08-30
AR093365A1 (es) 2015-06-03
TR201809507T4 (tr) 2018-07-23
SG11201502730SA (en) 2015-05-28
NZ707895A (en) 2019-07-26
HRP20181021T1 (hr) 2018-08-24
US20150335706A1 (en) 2015-11-26
HK1211215A1 (en) 2016-05-20
US11052128B2 (en) 2021-07-06
CA2890166C (en) 2023-08-15
TWI615158B (zh) 2018-02-21
CY1120391T1 (el) 2019-07-10
RS57394B1 (sr) 2018-09-28
RU2015121574A (ru) 2016-12-27
JP2015536938A (ja) 2015-12-24
ES2676468T3 (es) 2018-07-19
EP2916866A1 (de) 2015-09-16
WO2014072277A1 (de) 2014-05-15
MX2015005700A (es) 2015-08-20
EP2916866B1 (de) 2018-04-04
AU2013343638B2 (en) 2018-08-30
KR20150082328A (ko) 2015-07-15
PL2916866T3 (pl) 2018-10-31
CN104780940A (zh) 2015-07-15
IL238615A0 (en) 2015-06-30
JP6321667B2 (ja) 2018-05-09
RU2679124C2 (ru) 2019-02-06
DK2916866T3 (en) 2018-07-23
CA2890166A1 (en) 2014-05-15
LT2916866T (lt) 2018-07-25

Similar Documents

Publication Publication Date Title
ZA202102906B (en) Liquid protein formulations containing viscosity-lowering agents
WO2018083087A3 (en) Binding proteins
PH12015502621A1 (en) Estrogen receptor modulator and uses thereof
MX2019003716A (es) Formulaciones farmaceuticas de anticuerpos tnf-alfa.
MX367034B (es) Formulacion para dominios de union biespecificos de celulas-t (bites).
PH12014501351A1 (en) Fluorinated estrogen receptor modulators and uses thereof
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
MX2015011132A (es) Moduladores policiclicos del receptor de estrogenos y sus usos.
MX361681B (es) Composiciones de proteína estabilizadas basadas en alcanos semifluorados.
PH12015501737A1 (en) Androgen receptor modulators and uses thereof
AU2014284235B2 (en) Methods for treating nasal polyposis by administering an IL-4R antagonist
MX2013002975A (es) Moduladores de receptores de estrogenos y usos de los mismos.
MX2018004883A (es) Composiciones farmaceuticas de il-2.
EA201270815A1 (ru) Модуляторы рецепторов эстрогена и их применение
MX2016007865A (es) Peptidos citotoxicos y conjugados de los mismos.
NZ700733A (en) (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators
MX2014010537A (es) Moduladores de receptor x del higado (lxr) para el tratamiento de enfermedades, trastornos y condiciones dermicas.
MX2023000204A (es) Variantes de proteinas de union al factor h y metodos de uso de estas.
PH12014502596A1 (en) Pharmaceutical formulation
MX2016010030A (es) Proteina quimerica compuesta del dominio antagonista de factor de crecimiento nervioso secretado (ngf) y un dominio antagonista de factor alfa de necrosis tumoral (tnfa).
MX2013004693A (es) Composiciones de aripiprazol y metodos para su suministro transdermico.
AU2012280776B2 (en) Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases
MX2016002930A (es) Moduladores del receptor x hepatico (lxr).
NZ733351A (en) Combinations of modalities for the treatment of diabetes
WO2014151230A3 (en) Method of treating granulomatosis with polyangiitis

Legal Events

Date Code Title Description
FG Grant or registration